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Abstract 
Objective 
 The purpose of this review of literature is to evaluate the effects of cinnamon on hemoglobin A1C (HbA1c) and fasting blood 
glucose/fasting plasma glucose (FBG/FPG) in various populations such as type II diabetes, prediabetics, metabolic syndrome, and 
overweight or obese individuals.   
Research Design and Methods 
 A comprehensive literature review was done with the Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
database using the keywords, cinnamon, type II diabetes, diabetes, HbA1c, and FBS.  References used in previous meta-analysis were 
also searched and reviewed for inclusion.  Studies were included in this review if they evaluated cinnamon effects on HbA1c and/or 
FBS/FPG.  A total of 15 trials were incorporated in this literature review, 10 studied cinnamon’s effect on HbA1c levels and 13 
studied cinnamon’s effect on the FBG. 
Results 
 Six trials showed significant reductions in the HbA1c levels and 10 trials showed significant reductions in the FBG.    
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Conclusion 
 Based on this review of literature, cinnamon can be recommended as effective therapy for reducing HbA1c levels and FBG 
levels in type II diabetics.  To reduce FBG and HbA1c levels, cinnamon can be dosed at 1 g to 6 g daily with meals (i.e. one to four 
500 mg tablets BID or TID with meals).    
Cinnamon in the Treatment of Type II Diabetes 
 Diabetes affects people of all races, ethnicities, ages, and genders and can significantly alter quality of life, especially when not 
well controlled.  Conditions such as metabolic syndrome and prediabetes often result in diabetes within a few years.  Controlling these 
syndromes and diabetes becomes a dilemma when it is coupled with the cost of medications, for those with health insurance as well as 
for those without.  The United States Census Bureau stated that 42 million Americans did not have health insurance in 2013 (Smith & 
Medalia, 2014).  These individuals have the full burden of paying for their own health care costs.  The average cost of diabetic 
medications, supplies, and provider appointments, etc., is estimated at $13,700 per year (American Diabetes Association, 2015).  
Individuals suffering from the aforementioned prediabetic conditions and diabetes are often started on medications such as Metformin, 
and are seen quarterly by their providers; therefore, have increasing medical expenses as well.  Piette, Heisler, and Wagner (2004) 
stated, “Out-of-pocket medication costs pose a significant burden to many adults with diabetes” (p. 384).  As a result, 20% of diabetic 
patients forgo taking their medications, as prescribed, in an effort to reduce their out-of-pocket expenses (Piette, Heisler, & Wagner, 
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2004).  If diabetes is not well controlled, the long term effects can be costly, as well as deadly, as diabetes can lead to comorbidities 
such as neuropathy, retinopathy, nephropathy, hypertension, dermatological problems, and amputations, etc.  It is imperative that 
prediabetic states and diabetes be well controlled to improve the quality of life within these disease processes, and to reduce the long 
term cost of comorbidities associated with these illnesses.  New cost effective alternatives, such as cinnamon supplementation, need to 
be identified to help reduce long term side effects and the out-of-pocket expenses for prediabetic states and diabetes. 
Cinnamon has been widely used for decades as a dietary supplement for diabetes, especially in other countries like China, and 
there is increased awareness in the area of natural or alternative supplements in the United States due to costs and side effects 
associated with traditional pharmaceuticals, even though the Food and Drug Administration (FDA) does not regulate or manage the 
manufacturing of herbal remedies.  Shane-McWhorter (2013) found that 67% of diabetics used herbal supplements such as cinnamon 
to lower their blood glucose levels, which may imply a desire to self treat their diabetes.  Lu et al. (2012) found that “cinnamon 
supplementation is able to significantly improve blood glucose control in Chinese patients with type 2 diabetes” (p. 1).  Cinnamon has 
been shown to reduce insulin resistance, reduce blood glucose and lipid levels, reduce inflammation, and increase antioxidant activity 
(Qin, Panicker, & Anderson, 2010).  Despite these benefits and wide spread use of cinnamon and other natural supplements, most 
traditional providers in the United States do not prescribe or recommend cinnamon or other natural supplements.  This may be due to 
the lack of regulation and approval by the FDA and the lack of evidence of efficacy, or may be due to their own belief or perceptions 
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about cinnamon and other natural supplements.  Whatever the reason, there may not be enough information to influence providers to 
act.  Increased studies that show support for cinnamon use in the treatment of type II diabetes, metabolic syndrome, and prediabetes 
may be the cue to action that is needed. 
There are only a handful of studies that have been done on the effects of cinnamon in the treatment of type II diabetes and not 
all show positive results.  A few studies have been done on the effects of cinnamon on other disease processes as well as healthy 
individuals.  Wang et al. (2007) studied the effects of cinnamon on women with PCOS.  Results showed significant reductions in 
insulin resistance in the cinnamon group but not in the placebo group.  Solomon and Blannin (2007 & 2009) examined the effects of 
cinnamon on healthy individuals using OGTT.  Their trails showed that cinnamon 5 g and 3 g, respectively, can reduce glucose 
responses to OGTT and improve insulin sensitivity in healthy individuals.  Hlebowicz, Darwiche, Björgell, and Almér (2007) and 
Hlebowicz et al. (2009) also show the efficacy of cinnamon in healthy individuals on postprandial blood glucose, gastric emptying, 
satiety, serum insulin, GLP-1 concentrations, GIP, gherlin, and GER.  Prior meta-analysis have focused primarily on the type II 
diabetic population or have excluded studies that did not report specific biochemical markers like fasting blood sugar (FBS) (Davis & 
Yokoyama, 2011).  There is a need for a more comprehensive review of the effects of cinnamon on multiple biochemical measures as 
well as multiple disease processes. The purpose of this review of literature is to evaluate the effects of cinnamon on hemoglobin A1C 
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(HbA1c) and fasting blood glucose/fasting plasma glucose (FBG/FPG) in various populations such as type II diabetes, prediabetics, 
metabolic syndrome, and overweight or obese individuals.    
Theoretical Framework 
The theoretical framework utilized for this research proposal is the Health Belief Model applied mostly from the perspective of 
the provider.  This model theorizes that belief and perceptions influence actions (Glanz, & Rimer, 2005).  The researcher has predicted 
that there is a relationship between cinnamon therapy and reduction of some biochemical measures; however, providers do not 
currently prescribe or recommend its use.   
The Health Belief Model describes how modifiable variables and perceived ideas such as severity of consequences, 
susceptibility, benefits versus barriers, and cues to action can bring about the likelihood of engaging in actions that can promote health 
(Glanz, & Rimer, 2005).  Providers are aware of the susceptibility and severity of type II diabetes.  They can be educated about the 
perceived benefits of cinnamon, i.e., efficacy in lowering HbA1c levels and blood glucose levels, low cost, and no side effects (unless 
there is an allergy to cinnamon).  The perceived barriers to prescribing cinnamon are the lack of FDA regulation of cinnamon, lack of 
recommendation by the American Diabetic Association (ADA), lack of knowledge of the efficacy of cinnamon in lowering some 
biochemical measurements, and presumed lack of research to support its use.  Cues to actions may be evidence-based trials that show 
benefits and effectiveness of cinnamon in the treatment of type II diabetes and other disease states, while reducing variables such as 
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the dosing amount of cinnamon.  With knowledge of such trials, primary care providers may be influenced to act and prescribe this 
supplement.  Providers, therefore, will be promoting health and self sufficiency in their patients, as their patients will be less 
dependent on multiple medications, have fewer medication-induced side effects, and fewer medication-induced medical problems. 
Materials and Methods 
 A comprehensive literature review was done with the Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
database using the keywords, cinnamon, type II diabetes, diabetes, HbA1c, and FBS.  References used in previous meta-analysis were 
also searched and reviewed for inclusion.  Studies were included in this review if they evaluated cinnamon effects on HbA1c and/or 
FBS/FPG.  Studies on type I diabetes were excluded because type I diabetics have a deficiency of insulin rather than insulin 
resistance, and this literature review is focusing on insulin resistance.  Another study excluded was done by Wainstein et al. (2011) on 
type 2 diabetics because the cinnamon tablet contained cinnamon, zinc gluconate and tri-calcium phosphate.  Also not included in this 
review were studies done on rats.    
A total of 15 trials were incorporated in this literature review.  Thirteen of the trials studied the effects of cinnamon on type II 
diabetic participants, one trial assessed the effects of cinnamon on prediabetic and metabolic syndrome individuals, and one trial 
studied the efficacy of cinnamon use in overweight or obese individuals.  Of these trials, 10 measured HbA1c levels and 13 measured 
FBG.  Other biochemical markers were measured but are not part of this review. 
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Results 
HbA1c 
The HbA1c level measures the average blood sugars over a three month period, and is important in diabetic management 
because higher HbA1c levels denote greater risk of developing diabetes-related complications.  Crawford (2009) studied whether 1 
gram of cinnamon cassia taken daily for 90 days would lower HbA1c levels in poorly controlled type II diabetes.  Cinnamon 1 g daily 
was found to have lowered HbA1c levels by 0.83% (P < 0.001).  Usual care alone without cinnamon, lowered the HbA1c 0.37% (P < 
0.16).  Crawford concluded that cinnamon does lower HbA1c for this population.  Lu et al. (2012) also studied the effect of cinnamon 
on HbA1c levels for participants with type II diabetes.  Cinnamon extract prepared from the bark of Chinese Cinnamomum 
aromaticum was used.  In this study, they compared a placebo, low dose cinnamon (120mg), and high dose cinnamon (360mg).  The 
cinnamon or placebo tablets were taken every morning before breakfast for three months.  After three months, they found that for 
those in the low dose group, their HbA1c was reduced an average of 0.67% (8.90 + 1.24 to 8.23 + 0.99), (P = .003), and in the high 
dose group an average of 0.92% (8.92 + 1.35 to 8.00 + 1.00), (P = 0.0004).  In this study, the higher dose was more effective than the 
lower dose.   
The effect of cinnamon supplementation was again studied by Sharma, Sharma, Agrawal, Agrawal, and Singhal (2012) in 
newly diagnosed type II diabetics.  One hundred fifty newly diagnosed type II diabetics were stabilized with diet and exercise for one 
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month prior to beginning the cinnamon supplementation.  The participants were randomized into:  a 3 g cinnamon group, a 6 g 
cinnamon group, a placebo group.  After three months, it was found that for the 3 g group (taking 1 g after each meal) the HbA1c went 
from 8.47 +/- 1.02 at baseline to 7.29 +/- 0.83 post intervention, p < 0.005.  In the 6 g group (taking 2 g after each meal), the HbA1c 
went from 8.10 +/- 0.84 at baseline to 7.25 +/- 0.81 post intervention, p < 0.005.  Both doses had equivalent efficacy.  Vafa et al. 
(2012) treated type II diabetes with Cinnamomum zeylanicum.  Participants took two 500 mg tablets of Cinnamomum zeylanicum at 
each main meal for eight weeks, for a total of 3 grams daily.  The researchers concluded that cinnamon significantly decreased HbA1c 
(P = 0.008), of the treatment group, compared to the placebo group.  It is noted that even though the HbA1c levels of these participants 
were well controlled at baseline (7.35 + 0.51) the Cinnamomum zeylanicum was still effective in significantly reducing the mean level 
overall. 
Al-Yasiry, Kathum, and Al-Ganimi (2014) studied the hypoglycemic effect of cinnamon on 40 poorly controlled male type II 
diabetics.  The participants were given 0.5 g of ground crude cinnamon 15 minutes after each meal for a total of 1.5 g daily for three 
months.  They found that using 1.5g of ground cinnamon daily decreased the HbA1c which went from 9.54 + 0.96 pretreatment to 
8.22 + 0.65 post treatment, (P < 0.01).   
Cinnamon cassia usage in type II diabetics was studied by Akilen, Tsiami, Devendra, Robinson (2010).  Participants were 
given one 500 mg tablet of cinnamon cassia with breakfast and dinner and two 500 mg tablets with lunch, for a total of 2 g daily.  The 
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ingestion of 2 g of cinnamon each day was found to significantly reduce the HbA1c level, 8.22 + 1.16 to 7.86 + 1.42, p < 0.05.  A 
moderate positive correlation was found between the baseline HbA1c level and the significant drop of the HbA1c level suggesting that 
cinnamon supplementation for poorly controlled diabetics may play a positive role in managing their disease, r = 0.567, P = 0.008.  
 Four studies found no significant difference in the HbA1c levels with the use of cinnamon.  Vanschoonbeek, Thomassen, 
Senden, Wodzig, and van Loon (2006) investigated the effects of 1.5 g per day of cinnamon cassia on HbA1c levels of 25 
postmenopausal women with well controlled type II diabetes over a six week time frame.  No significant changes were found.  It must 
be noted that an appropriate amount of time was not given for a change to be properly noted in the HbA1c level as this trial was done 
over six weeks instead of three months.  Blevins, Leyva, Brown, Wright, Scofield, and Aston (2007) also showed no significant results 
of cinnamon on HbA1c levels.  For three months, cinnamon cassia 1 g was given daily.  It was found that this dosage of cinnamon 
given daily for three months produced no significant change in HbA1c levels (P > 0.05).  Mang et al. (2006) studied the effects of 3 g 
cinnamon daily on 79 type II diabetics over 4 months.   Their study showed no significant decrease in the HbA1c levels post 
treatment.  Suppapitiporn and Kanpaksi (2006) examined the efficacy of cinnamon cassia 1.5 g daily on reducing the HbA1c levels of 
60 type II diabetics.  After 12 weeks of intervention, it was found that the HbA1c levels decreased in both the placebo group and the 
cinnamon group.  There was a greater reduction of the HbA1c level in the cinnamon group, and more patients in the cinnamon group 
achieved a HbA1c level of < 7% as compared to the placebo group; however, the reductions were not statistically different, p > 0.05.   
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The participants in the Vanschoonbeek et al., 2006 trial, the Blevins et al., 2007 trial, and the Mang et al., 2006 trial were all 
well controlled diabetics with baseline HbA1c levels of 6.86 to 7.4.  DeFronzo, Stonehouse, Han, and Wintle (2010) did a meta- 
analysis of 59 trials with a total of 8479 patients on the relationship of baseline HbA1c levels and the effectiveness of 10 different 
classes of hyperglycemic medications and produced a weighted R2 of 0.35 (P < 0.0001).  These results show a positive correlation 
between the baseline HbA1c levels and magnitude of change of the HbA1c level after treatment with glucose-reducing therapies 
regardless of drug classification.  They further state that “These observations should be considered when assessing clinical efficacy of 
diabetes therapies derived from clinical trials, particularly when evaluating data from clinical trials of patients with relatively low 
baseline HbA1c levels, 7.0 – 8.0% (DeFronzo, Stonehouse, Han, & Wintle, 2010, p.309, 314).”  Lower baseline HbA1c levels prior to 
intervention produce smaller and less significant changes in the HbA1c levels post intervention. 
FBG/FPG   
The most common test used to diagnose diabetes is the fasting blood glucose level.  This test is more definitive than random 
blood glucose tests because it measures the blood glucose level after a period of at least eight hours of fasting (no food or liquids 
except water) eliminating the chance that the results have been influenced by recent food or beverage intake (OneTouch, no date).  
Khan, Safdar, Ali Khan, Khattak, and Anderson (2003) conducted the first in vivo study on the use of cinnamon in improving FBG 
levels.  Cinnamon cassia was given 1 g daily as one 500 mg table taken at lunch and dinner, 3 g daily as two 500 mg tablets taken at 
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breakfast, lunch, and dinner, or 6 g daily as four tablets taken at breakfast, lunch, and dinner.  The researchers found that all three 
doses of cinnamon reduced the mean FBG serum levels (18-29%, P < 0.05) of the participants in the treatment groups after 20, 40, and 
60 days.    
Anderson et al. (2010) studied the effects of cinnamon cassia 250 mg given twice a day to participants with type II diabetes.  
After two months it was found that the FBS decreased from 8.85 + 0.32 pretreatment to 8.19 + 0.29 mmol/L post treatment, p < 0.001.  
Mang et al. (2006) evaluated the usage of cinnamon cassia 1 g daily for type II diabetics.  Participants took the cinnamon as prescribed 
for four months.  The cinnamon group was found to have a significant reduction in the FBG between baseline and post intervention 
levels (9.26 + 2.26 to 8.15 + 1.65 mmol/L, p < 0.001).  Ziegenfuss, Hofheins, Mendel, Landis, and Anderson (2006) evaluated the 
effects of Cinnulin PF 500 mg once a day (which is equivalent to 10 g whole cinnamon powder) on the FBG of prediabetic and 
metabolic syndrome participants.  After 12 weeks, the FBG levels decreased – 8.4% from 116.3 + 12.8 mg/dl to 106.5 + 20.1 mg/dL, 
p < 0.01.  The efficacy of Cinnulin PF was also studied by Roussel, Hininger, Benaraba, Ziegenfuss, and Anderson (2009) in reducing 
the FBG of overweight or obese subjects.  Cinnulin PF 250 mg was taken twice a day for 12 weeks.  The FBG dropped from 114 + 2.2 
to 102 + 4.3 mg/dL, p < 0.05, between pre and post treatment with Cinnulin PF.  Khan, Khan, and Shah (2010) studied the effects of 
1.5 g of ground cinnamon 1.5 g on the FBG of type II diabetic participants.  For 30 days the participants ingested 0.5 g of cinnamon 
three times a day with meals.  A significant reduction of the FBG was found with the use of cinnamon (216.3 + 52.7 to 163.3 + 44.9 
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mg/dL, p < 0.05).  In a three month trial, Lu et al. examined the efficacy of cinnamon cassia 120 mg and 360 mg daily in reducing the 
FBS in 60 Chinese participants who were type II diabetics.  Results showed a statistically significant decrease in both groups.   
Baseline FBG levels decrease from 9.00 to 7.99 mmol/L in the 120 mg group, and from 11.21 to 9.59 mmol/L in the 360 mg group, (P 
= 0.00008). 
The effects if cinnamon in newly diagnosed type II diabetics was studied by Sharma, Sharma, Agrawal, Agrawal, and Singhal 
(2012).  One hundred and fifty participants were divided into three groups and given a placebo, 3 g cinnamon, or 6 g cinnamon daily 
spread out over three meals.  FBG levels were drastically reduced in both cinnamon groups.  Baseline FBG levels decreased 49% in 
the 3 g cinnamon group from 226.73 + 21.43 to 115.5 + 23.03, and 48% in the 6 g cinnamon group from 216.94 + 26.27 to 112.26 + 
22.85, (p < 0.001).  The effectiveness of Cinnamomum zeylanicum in the reduction of FBG was assessed by Vafa et al. (2012).  Two 
500 mg tablets were given to 37 subjects three times daily for eight weeks.  Cinnamomum zeylanicum, also known as true cinnamon, 
significantly reduced the FBG in the cinnamon group 139.28 + 9.11 to 126.47 + 17.73, (P < 0.05).  Al-Yasiry, Kathum, and Al-
Ganimi (2014) determined the hypoglycemic effects of cinnamon on 40 poorly controlled male type II diabetics.  Participants were 
given 1.5 g cinnamon daily for 3 months.   Cinnamon cassia produced a 27.5% decline in the FBG of the participants, 174.70 + 19.83 
to 126.25 + 17.85, (P < 0.01). 
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 In contrast, some trials found no significant reduction in FBG levels after cinnamon supplementation.  Vanschoonbeek, 
Thomassen, Senden, Wodzig, and van Loon (2006) investigated the effects of cinnamon 1.5 g on FBG levels of 25 postmenopausal 
women with well controlled type II diabetes over six weeks.  Although there was some decline of the FBG in the cinnamon group, 
8.37 + 0.59 to 7.91 + 0.71, it was not statistically significant, (P > 0.05).  Suppapitiporn and Kanpaks (2006) evaluated the effects of 
cinnamon cassia 1.5 g daily, taken over 12 weeks, on type II diabetics.  No statistical significance was found in the FBG.     
Blevins et al. (2007) explored the effects of 1 g cinnamon cassia on 57 non-insulin dependent type II diabetics.  After a three month 
intervention phase, no significant change was noted in the FBG. 
Discussion and Implications for Practice 
The global prevalence of diabetes was estimated at 9% in 2014 in individuals 18 and over.  That is over 350 million people 
worldwide (World Health Organization, no date) (WHO).  Diabetes significantly affects quality of life and leads to death when not 
well controlled.  Over 3 million people die of diabetes and its comorbidities yearly.   Centers for Disease Control and Prevention 
(2014a, 2014b)(CDC) states that diabetes was the 7th leading cause of death in 2010.  The American Diabetic Association estimates 
the cost of diabetes at $13,700 yearly per person, making diabetes costly as well as deadly.  Controlling diabetes and its predecessor 
diseases, prediabetes and metabolic syndrome is imperative to improving the health of our country and reducing health care 
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expenditures.  Finding safe, efficacious, and cost effective alternative treatments for diabetes is a must.  Cinnamon is a promising 
alternative treatment that has been used for decades as a dietary supplement for diabetes. 
Based on this review of literature, cinnamon can be recommended as effective therapy for reducing HbA1c levels and FBG 
levels in type II diabetics.  Cinnamon was also found to be effective in lowering FBG levels in prediabetics, overweight and obese 
individuals.  Cinnamon cassia, Cinnamomum zeylanicum, and Cinnulin PF have been shown to have similar efficacy in these 
populations; however, Cinnamomum zeylanicum may be more advantageous when diabetes is more controlled (Akilen, Tsiami, 
Devendra, and Robinson, 2010).  This review of literature recommends cinnamon as an efficacious and cost effective treatment of 
uncontrolled type II diabetes which may potentially have some cardiovascular benefits.  To reduce FBG and HbA1c levels, cinnamon 
can be dosed at 1 g to 6 g daily with meals (i.e. one to four 500 mg tablets BID or TID with meals).  No adverse effects were seen with 
any of the cinnamon doses.  Patients should be watched for cinnamon allergies, although none were reported in any of the studies 
reviewed.  
Conclusion 
 Further research needs to be done to evaluate if cinnamon is as equally effective in reducing the HbA1c level and FBG level in 
the stable type II diabetic (HbA1c level < 8.0 or FBG < 183) versus the unstable type II diabetic (HbA1c > 8.0 or FBG > 183, as well 
as the effectiveness of various types of cinnamon such as, cinnamon cassia, Cinnamomum zeylanicum, and Cinnulin PF. 
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Literature Review Matrix 
 
Needs to be 
full reference 
Purpose Design Independent Dependent Results 
1. Khan, A., 
Safdar, M., 
Ali Khan, M. 
M., Khattak, 
K. N., & 
Anderson, R. 
A. (2003). 
Cinnamon 
improves 
glucose and 
lipids of 
people with 
type 2 
diabetes. 
Diabetes 
Care, 26(12), 
3215-3218.   
The objective of this 
study was to 
determine whether 
cinnamon improves 
blood glucose, 
triglyceride, total 
cholesterol, HDL 
cholesterol, and LDL 
cholesterol levels in 
people with type 2 
diabetes. 
A total of 60 people 
with type 2 diabetes, 
were divided 
randomly into six 
groups. Groups 1, 2, 
and 3 consumed 1, 
3, or 6 g of 
cinnamon daily, 
respectively, and 
groups 4, 5, and 6 
were given placebo 
capsules 
corresponding to the 
number of capsules 
consumed for the 
three levels of 
cinnamon. The 
cinnamon was 
consumed for 40 
days followed by a 
20-day washout 
period. 
Cinnamon cassia 
one 500mg tablet 
taken at lunch 
and dinner for 1g 
dose. 
 
Cinnamon cassia 
two 500mg 
tablets taken at 
breakfast, lunch 
and dinner for 3g 
dose. 
  
Cinnamon cassia 
four 500mg 
tablets taken at 
lunch and dinner 
for 6 g dose. 
 
 
 FBG levels  
 Lipid levels 
After 40 days, all three levels 
of cinnamon reduced the 
mean fasting serum glucose 
(18–29%), triglyceride (23–
30%), LDL cholesterol (7–
27%), and total cholesterol 
(12–26%) levels; no 
significant changes were 
noted in the placebo groups. 
Changes in HDL cholesterol 
were not significant. 
2. Lu, T., We hypothesized To address this Chinese adults >  HbA1c levels  Placebo group had no 
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Sheng, H., 
Wu, J., 
Cheng, Y., 
Zhu, J., & 
Chen, Y. 
(2012). 
Cinnamon 
extract 
improves 
fasting blood 
glucose and 
glycosylated 
hemoglobin 
level in 
Chinese 
patients with 
type 2  
diabetes. 
Nutrition 
Research 
(New York, 
N.Y.), 32(6), 
408-412.  
doi:10.1016/j
.nutres.2012.
05.003.  
 
cinnamon should be 
effective in 
improving blood 
glucose control in 
Chinese patients with 
type 2 diabetes.  This 
study was done to to 
analyze the effect of 
cinnamon extract on 
glycosylated 
hemoglobin A1c and 
fasting blood glucose 
levels. 
hypothesis, we 
performed a 
randomized, double-
blinded clinical 
study in Chinese 
patients with type 2 
diabetes. A total of 
66 patients with type 
2 diabetes were 
recruited and 
randomly divided 
into 3 groups: 
placebo and low-
dose and high-dose 
supplementation 
with cinnamon 
extract at 120 and 
360 mg/d, 
respectively. 
Patients in all 3 
groups took 
gliclazide during the 
entire 3 months of 
the study. 
age 48 with type 
II diabetes.                
Low dose 
cinnamon 
120mg.          
High dose 
cinnamon 
360mg.         
Cinnamon 
extract tablets, 
60 mg each, 
prepared from 
the bark of 
Chinese 
Cinnamomum 
aromaticum 
 
 FBG levels  
 triglycerides 
 HDL  
 LDL  
 total cholesterol  
 liver 
transaminase 
 
significant change in pre & 
post HA1C or FBG.  Both the 
HbA1c and FBG levels were 
significantly reduced in post 
treatment in the low and high 
dose groups. HbA1c reduced 
an average of 0.67% (P = 
.003) in the low dose group 
and reduced an average of 
0.92% (P = 0.0004) in the 
high dose group.  The FBG 
reduced an average of 1.10 
mmol/L (P = .002)in the low 
dose group and reduced an 
average of 1.62 mmol/L (P = 
.00008) in the high dose 
group.    Triglyceride levels 
were reduced in the low dose 
group (P = .007).  Total 
cholesterol, HDL, LDL, and 
liver transaminases remained 
unchanged in the 3 groups. 
 
3. Crawford, 
P. (2009). 
Multiple trials in the 
past have shown 
109 type 2 diabetics 
(HbA1C >7.0) were 
Cinnamon 
Cassia 500 mg 2 
 HbA1c levels  
 
Cinnamon lowered HbA1c 
0.83% (95% Cl, 0.46 - 1.20) 
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Effectiveness 
of cinnamon 
for lowering 
hemoglobin 
A1C in 
patients with 
type 2 
diabetes: A 
randomized, 
controlled 
trial. Journal 
of the 
American 
Board of 
Family 
Medicine : 
JABFM, 
22(5), 507-
512. 
doi:10.3122/j
abfm.2009.0
5.080093 
 
conflicting results of 
whether cinnamon 
lowers glucose or 
hemoglobin A1C 
(HbA1C). The 
purpose of this study 
was to determine 
whether cinnamon 
lowers HbA1C in 
patients with type 2 
diabetes. In this study 
a randomized, 
controlled trial was 
performed to evaluate 
whether daily 
cinnamon plus usual 
care versus usual care 
alone lowers HbA1c. 
randomized from 3 
primary care clinics 
caring for pediatric, 
adult, and geriatric 
patients at a United 
States military base. 
Participants were 
randomly allocated 
to either usual care 
with management 
changes by their 
primary care 
physician or usual 
care with 
management 
changes plus 
cinnamon capsules, 
1g daily for 90 days. 
HbA1c was drawn at 
baseline and 90 days 
and compared with 
intention-to-treat 
analysis. This study 
was approved by an 
institutional review 
board. 
tabs daily   
 
Usual diabetic 
medications, no 
placebo 
(P < .001) compared with 
usual care alone lowering 
HbA1c 0.37% (95% Cl, 0.15 - 
0.59) (P < .16).   
 
4. Sharma, 
P., Sharma, 
S., Agrawal, 
The aim of this study 
was to evaluate 
efficacy of cinnamon 
One hundred and 
fifty newly 
diagnosed 
 Cinnamon 1 g 
capsules at 
breakfast, lunch 
 HbA1c levels  
 FBG levels  
 SBP 
After three months of 
supplementation there was a 
significant improvement in 
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R., P., 
Agrawal, V., 
& Singhal, S. 
(2012). A 
randomized 
double blind 
placebo 
control trial 
of cinnamon 
supplementat
ion on 
glycemic 
control and 
lipid profile 
in type 2 
diabetes 
mellitus. 
Australian 
Journal of 
Herbal 
Medicine, 
24(1), 4-9. 
Retrieved 
from 
supplementation on 
blood sugar, HbA1c, 
serum cholesterol, 
triglyceride, LDL, 
and HDL levels in 
newly diagnosed type 
2 diabetes mellitus 
(T2DM).   
individuals with 
T2DM were selected 
randomly.  After one 
month stabilization 
period, 150 patients 
were divided into 
three groups 1, 2, 
and 3 given type A, 
B, C capsules 
blindly bearing 
distinctive code 
number.  All three 
groups were also 
given conventional 
treatment i.e. diet 
and exercise for 3 
months.  
Antropometric 
parameters, blood 
pressure, blood 
sugar, HbA1c and 
lipid profiles were 
preformed initially 
after 1 and 3 months 
of treatment.  After 3 
months decoding 
was done and 
analyzed data by 
ANOVA, t and r 
and dinner for 
3g daily 
 Cinnamon 2 g 
capsules at 
breakfast, 
lunch, and 
dinner for   6g 
daily (Type -
extract or cassia 
not specified) 
 Time – 0, 1, and 
3 months 
 Conventional 
treatment of diet 
and exercise 
 
 Cholesterol  
 HDL 
 LDL 
 Triglycerides 
 BMI 
 
FBS and HbA1c in both 
groups (3 gm FBS was 226.73 
+/- 21.43 to 115.6 +/- 23.03, p 
< 0.001, in HbA1c 8.47 +/- 
1.02 to 7.29 +/- 0.83, p < 
0.005, in 6 gm FBS was 
216.94 +/- 26.27 to 112.26 +/- 
22.85 and HbA1c was 8.10 
+/- 0.84 to 7.25 +/- 0.81, p < 
0.005). In BMI no significant 
difference was observed. 
There was a significant 
difference in systolic blood 
pressure (3 gm doses 130.75 
+/- 14.10 to 126.60 +/- 13.16, 
p < 0.005, and in 6 gm 126.8 
+/- 13.73 to 121.65 +/- 11.34, 
p < 0.001). In 3 gm doses 
changes in cholesterol level, 
LDL, triglyceride and HDL 
were significant (190.16 +/- 
25.19 to 164 +/- 17.82; 
109.69 +/- 14.89 to 96.80 +/- 
8.77; 213.5 +/- 40.14 to 
146.04 +/- 38.34 and 40.148 
+/- 6.16 to 45.43 +/- 0.27, p < 
0.001, respectively). In 6 gm 
cholesterol was 188.04 +/- 
20.83 to154.31 +/- 17.94; 
CINNAMON IN THE TREATMENT OF TYPE II DIABETES     26 
   
 
 
https://ezprox
y.southern.ed
u/login?url=h
ttp://search.e
bscohost.com
/login.aspx?d
irect=true&d
b=ccm&AN=
2011688521
&site=ehost-
live&scope=s
ite 
test. LDL 102.51 +/- 21.70 to 
90.85 +/- 19.10; triglyceride 
206.50 +/- 72.50 to147.28 +/- 
51.29 and HDL was 43.73 +/- 
11.77 to 69.78 +/- 8.66, p < 
0.001. 
 
5. Anderson, 
R. A., Zhan, 
Z., Luo, R., 
Guo, X., 
Guo, Q., 
Zhou, J., . . . 
Stoecker, B. 
J. (2010).  
Cinnamon 
extract 
lowers 
glucose, 
insulin and 
cholesterol in 
people with 
The purpose of this 
study was to evaluate 
the effects of 
cinnamon on 
circulating glucose, 
lipids, insulin, and 
insulin resistance in 
the Chinese 
population. 
A total of 137 
Chinese participants 
with type 2 diabetes 
were randomly 
assigned to two 
groups in this double 
blind placebo-
controlled trial.  The 
cinnamon group 
took one 250 mg 
cinnamon capsule 
BID for a total of 
500 mg.  The control 
group received 
placebo capsules 
 Cinnamon 
cassia water 
dried extract 
250 mg BID for 
a total of 500 
mg for 2 
months 
 100 g of white 
steamed bread 
(equivalent to 
75 g of 
carbohydrate) 
 Fasting and 2 
hour serum 
blood glucose 
 Insulin resistance  
 Serum lipids 
 Fructosamine 
 SBP & DBP 
 
After 2 mo, fasting glucose 
decreased (p < 0.001) in the 
cinnamon extract-
supplemented group 
(8.85 ± 0.36 to 
8.19 ± 0.29 mmol/L) 
compared with the placebo 
group (8.57 ± 0.32 to 
8.44 ± 0.34 mmol/L, 
p = 0.45). Glucose 2 h after a 
75 g carbohydrate load, 
fasting insulin, and HOMA-
IR also decreased with 
cinnamon extract compared 
with placebo. Total and LDL-
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elevated 
serum 
glucose. 
Journal of 
Traditional 
and 
Complement
ary 
Medicine, 
doi:  
10.1016/jtcm
e.2015.03.00
5 
which contained 250 
mg of dark brown 
(baked) wheat flour 
and were very 
similar in 
appearance to the 
cinnamon extract.   
cholesterol decreased with 
cinnamon extract and HDL-
cholesterol decreased in both 
the cinnamon-extract and 
placebo groups. In 
conclusion, supplementation 
with 500 mg of water-extract 
of cinnamon for two months 
reduced fasting insulin, 
glucose, total cholesterol, and 
LDL cholesterol and 
enhanced insulin sensitivity of 
subjects with elevated blood 
glucose. 
 
6. Vafa, M., 
Mohammadi, 
F., Shidfar, 
F., Sormaghi, 
M. S., 
Heidari, I., 
Golestan, B., 
& Amiri, F.  
(2012). 
Effects of 
cinnamon 
consumption 
on glycemic 
status, lipid 
The purpose of this 
study was to evaluate 
the effects of the 
daily intake of three 
grams cinnamon over 
eight weeks on 
glycemic status, lipid 
profiles and body 
composition in type 2 
diabetic patients. 
A double blind, 
randomized, placebo 
controlled, 
clinical trial was 
conducted on 44 
patients with type 2 
diabetes. 
Participants were 
randomly assigned 
to take either a three 
g per 
day cinnamon 
supplement (n=22) 
or a placebo (n=22) 
 Cinnamon 
zeylanicum 
(cinnamon 
verum or "true 
cinnamon") 500 
mg 2 tabs at 
each main meal 
daily for total of 
3 g daily for 
eight weeks 
 FBG levels  
 HbA1c 
 Triglyceride 
 Weight 
 BMI and body 
fat mass 
 
From 44 subjects participated 
in this study 37 completed 
the study. There were no 
significant differences in 
baseline 
characteristics, dietary intake 
and physical activity between 
groups. 
In the treatment group, the 
levels of fasting blood 
glucose, HbA1c, 
triglyceride, weight, BMI and 
body fat mass decreased 
significantly 
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profile and 
body  
composition 
in type 2 
diabetic 
patients. 
International 
Journal of 
Preventive 
Medicine,  
3(8), 531. 
 
for eight 
weeks. Weight, 
height, body fat 
mass and systolic 
and diastolic 
blood pressure were 
measured at baseline 
and after 
intervention. 
The fasting blood 
glucose, insulin, 
HbA1c, total 
cholesterol, LDL 
C, HDL C, Apo 
lipoprotein A I and 
B were measured at 
baseline 
and endpoint. 
 
compared to baseline, but not 
in placebo group. No 
significant 
differences were observed in 
glycemic status indicators, 
lipid 
profile and anthropometric 
indicators between the groups 
at the 
end of intervention. 
 
7. 
Vanschoonbe
ek, K., 
Thomassen, 
B. J., Senden, 
J. M., 
Wodzig, W. 
K., & van 
Loon, L. J. 
(2006).  
The objective of this 
study was to 
investigate the effects 
of cinnamon 
supplementation on 
insulin sensitivity 
and/or glucose 
tolerance and blood 
lipid profile in 
patients with type 2 
A total of 25 
postmenopausal 
women diagnosed 
with type 2 diabetes 
were selected to 
participate in this 
study.  Subjects 
were assigned to a 
control (n = 13) or 
placebo group (n = 
 Cinnamon 
Cassia 1 500 
mg capsule at 
breakfast, 
lunch, and 
dinner daily for 
total of 1500 
mg daily  
 Time – 0, 2, and 
6 weeks                
 FPG levels  
 Whole-body 
insulin 
sensitivity 
 Glucose 
tolerance 
 Blood lipid 
levels 
 
No significant changes were 
noted in whole-body indices, 
fasting plasma glucose, 
HbA1c, glucose tolerance, or 
blood lipid profile compared 
to placebo group after 
cinnamon supplementation (P 
> 0.05).   We conclude that 
cinnamon supplementation of 
1.5 g/d does not improve 
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Cinnamon 
supplementat
ion does not 
improve 
glycemic 
control in 
postmenopau
sal type 2  
diabetes 
patients. The 
Journal of 
Nutrition, 
136(4), 977-
980. 
doi:136/4/97
7 [pii] 
 
diabetes. 12), matched for 
age, BMI, years 
since diagnosis with 
type 2 diabetes, 
fasting blood 
glucose 
concentration, and 
medication.  
Subjects were 
studied over a 6- to 
7-wk period in a 
double-blind, 
placebo-controlled 
trial.  Whole-body 
insulin sensitivity or 
oral glucose 
tolerance were 
estimated by 
performing an 
OGTT before (wk 0) 
and after 2 (wk 2) 
and 6 wk (wk 6) of 
supplementation. 
whole-body insulin sensitivity 
or oral glucose tolerance and 
does not modulate blood lipid 
profile in postmenopausal 
patients with type 2 diabetes. 
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8. Blevins, S. 
M., Leyva, 
M. J., Brown, 
J., Wright, J., 
Scofield, R. 
H., & Aston, 
C. E. (2007). 
Effect of 
cinnamon on 
glucose and 
lipid levels in 
non insulin-
dependent 
type 2 
diabetes.  
Diabetes 
Care, 30(9), 
2236-2237. 
doi:dc07-
0098 [pii] 
 
The purpose of this 
study was to report 
the effects of 
cinnamon on lipid 
levels and glucose in 
the Western diabetic 
population. 
This trial was 
randomized double 
blinded placebo 
controlled trial with 
57 subjects.  
Enrolled subjects 
received either 500 
mg of cinnamon 
cassia or placebo 
(wheat flour) 
capsules.  Subjects 
were instructed to 
ingest one capsule 
with breakfast and 
one with dinner for 3 
months.   
 Cinnamon 
Cassia one 500 
mg capsule at 
breakfast and 
dinner totaling 
1g daily 
 Time – 1, 2, 3 
months 
 FBG levels 
 Lipid levels 
 HbA1c 
 Insulin levels          
Cinnamon intake of 1g daily 
for 3 months produced no 
significant change in fasting 
glucose, lipids, HbA1c, or 
insulin levels from baseline to 
1, 2, and 3 months (P > 0.05). 
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9. Akilen, R., 
Tsiami, A., 
Devendra, 
D., & 
Robinson, N. 
(2010). 
Glycated 
haemoglobin 
and blood  
pressure‐low
ering effect 
of cinnamon 
in 
multi‐ethnic 
Type 2 
diabetic 
patients in 
the UK: a 
randomized, 
placebo‐contr
olled, 
double‐blind 
clinical trial. 
Diabetic 
Medicine, 
27(10), 
  
1159-1167. 
 
The purpose of this 
study was to 
determine the blood 
glucose lowering 
effect of cinnamon on 
HbA1c, blood 
pressure, and lipid 
profiles in people 
with type 2 diabetes.   
Fifty eight type 2 
diabetic patients (25 
males and 33 
females) treated only 
with hypoglycemic 
agents and with a 
HbA1c more than 
7% were randomly 
assigned to receive 
either 2 g of 
cinnamon or placebo 
daily for 12 weeks.   
 Cinnamon 
cassia four 500 
mg capsules 
daily, one with 
breakfast, two 
with lunch, and 
one with dinner 
for 12 weeks 
 Four 500 mg 
starch-filled 
placebo 
capsules daily, 
one with 
breakfast, two 
with lunch, and 
one with dinner 
for 12 weeks 
 
 HbA1c 
 SBP 
 DBP 
 
After intervention, the mean 
HbA1c was significantly 
decreased (P<0.005) in the 
cinnamon group (8.22% to 
7.86%) compared with 
placebo group (8.55% to 
8.68%). Mean systolic and 
diastolic blood pressures 
(SBP and DBP) were also 
significantly reduced 
(P<0.001) after 12 weeks in 
the cinnamon group (SBP: 
132.6 to 129.2 mmHg and 
DBP: 85.2 to 80.2 mmHg) 
compared with the placebo 
group (SBP: 134.5 to 134.9 
mmHg and DBP: 86.8 to 86.1 
mmHg). A significant 
reduction in fasting plasma 
glucose (FPG), waist 
circumference and body mass 
index (BMI) was observed at 
week 12 compared to baseline 
in the cinnamon group, 
however, the changes were 
not significant when 
compared to placebo group. 
There were no significant 
differences in serum lipid 
CINNAMON IN THE TREATMENT OF TYPE II DIABETES     32 
   
 
 
profiles of total cholesterol, 
triglycerides, HDL and LDL 
cholesterols, neither between 
nor within the groups. 
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10. Al-
Yasiry, K., 
Kathum, W., 
& Al-
Ganimi, Y. 
(2014). 
Evaluation of 
Anti-Diabetic 
Effect of  
Cinnamon in 
Patients with 
Diabetes 
Mellitus 
Type Ii in 
Kerbala City. 
Journal of 
Natural  
Sciences 
Research, 
4(4), 43-45. 
 
This study aimed to 
determine the 
hypoglycemic effect 
of cinnamon in 
patients with type 2 
diabetes as adjuvant 
therapy. 
Forty male patients 
with type 2 diabetes 
taking oral anti-
diabetic drug(s) 
were randomly 
selected for this 
quasi-experimental 
trial.  They were 
given a crude grind 
cinnamon 15 
minutes after each 
meal for 3 months.   
 0.5 gm 
Cinnamon 
(crude, ground) 
after each meal, 
totaling 1.5 gm 
daily for 3 
months 
 
 FBS 
 RBS 
 HbA1c 
 Weight 
 
Results showed cinnamon had 
a significant antidiabetic 
effect in reduction of FBS, 
RBS, & HbA1c.  No 
significant results were seen 
in reduction of body weight 
(P < 0.01). 
11. Mang, B., 
Wolters, M., 
Schmitt, B., 
Kelb, K., 
Lichtinghage
n, R., 
Stichtenoth, 
D. O., & 
The aim of this trial 
was to determine 
whether an aqueous 
cinnamon purified 
extract improves 
glycated 
haemoglobin A1c 
(HbA1c), fasting 
A total of 79 patients 
with diagnosed 
diabetes mellitus 
type 2 not on insulin 
therapy but treated 
with oral 
antidiabetics or diet 
were randomly 
 Cinnamon 
cassia (aqueous 
cinnamon 
extract) 112 mg 
capsules which 
corresponds to 1 
g of cinnamon 
for a total of 3 g 
 FPG 
 HbA1c 
 Lipid levels 
 
The mean absolute and 
percentage differences 
between the pre- and post-
intervention fasting plasma 
glucose level of the cinnamon 
and placebo groups were 
significantly different. There 
was a significantly higher 
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Hahn, A. 
(2006). 
Effects of a 
cinnamon 
extract on 
plasma 
glucose, 
HbA1c, and 
serum lipids 
in  
diabetes 
mellitus type 
2. European 
journal of 
clinical 
investigation, 
36(5), 340-
344. 
 
plasma glucose, total 
cholesterol, low-
density lipoprotein 
(LDL), high-density 
lipoprotein (HDL) 
and triacylglycerol 
concentrations in 
patients with type 2 
diabetes. 
assigned to take 
either a cinnamon 
extract or a placebo 
capsule three times a 
day for 4 months in 
a double-blind study. 
A total of 65 
subjects completed 
the study.  The 
amount of aqueous 
cinnamon extract 
corresponded to 3 g 
of cinnamon powder 
per day. 
daily for 4 
months 
 Placebo 
capsules 
containing 
microcrystalline 
cellulose only 
reduction in the cinnamon 
group (10·3%) than in the 
placebo group (3·4%). No 
significant intragroup or 
intergroup differences were 
observed regarding HbA1c, 
lipid profiles or differences 
between the pre- and 
postintervention levels of 
these variables. The decrease 
in plasma glucose correlated 
significantly with the baseline 
concentrations, indicating that 
subjects with a higher initial 
plasma glucose level may 
benefit more from cinnamon 
intake. No adverse effects 
were observed. 
12. 
Ziegenfuss, 
T. N., 
Hofheins, J. 
E., Mendel, 
R. W., 
Landis, J., & 
Anderson, R. 
A. (2006). 
Effects of a 
The purpose of this 
study was to 
determine the effects 
of supplementation 
with a water-soluble 
cinnamon extract 
(Cinnulin PF®) on 
body composition 
and features of the 
metabolic syndrome. 
Twenty-two subjects 
with prediabetes and 
the metabolic 
syndrome were 
randomly assigned 
to supplement their 
diet with either 
Cinnulin PF® (500 
mg/d) or a placebo 
for 12-weeks. Main 
 Cinnulin PF two 
250 mg 
capsules BID 
with breakfast 
and dinner daily 
for a total of 1g 
daily (500 mg 
of Cinnulin is 
equivalent to 10 
g of whole 
 FBG 
 SBP 
 Body mass 
 
Subjects in the Cinnulin PF® 
group had significant 
decreases in FBG (-8.4%: 
116.3 ± 12.8 mg/dL [pre] to 
106.5 ± 20.1 mg/dL [post], p 
< 0.01), SBP (-3.8%: 133 ± 
14 mm Hg [pre] to 128 ± 18 
mm Hg [post], p < 0.001), and 
increases in lean mass 
(+1.1%: 53.7 ± 11.8 kg [pre] 
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water-soluble 
cinnamon 
extract on 
body 
composition 
and features 
of the 
metabolic  
syndrome in 
pre-diabetic 
men and 
women. 
Journal of 
the 
International 
Society of 
Sports  
Nutrition, 
3(2), 45. 
 
outcome measures 
were changes in 
FBG, SBP, and body 
composition 
measured after 12-
weeks of 
supplementation.  
cinnamon 
powder, i.e., 
20:1 extract) 
 Placebo two 
250 mg 
capsules BID 
with breakfast 
and dinner daily 
for a total of 1g 
daily (substance 
of placebo 
capsule not 
specified) 
to 54.3 ± 11.8 kg [post], p < 
0.002) compared with the 
placebo group. Additionally, 
within-group analyses 
uncovered small, but 
statistically significant 
decreases in body fat (-0.7%: 
37.9 ± 9.2% [pre] to 37.2 ± 
8.9% [post], p < 0.02) in the 
Cinnulin PF® group. No 
significant changes in clinical 
blood chemistries were 
observed between groups over 
time. 
13. 
Suppapitipor
n, S., & 
Kanpaksi, N. 
(2006). The 
effect of 
cinnamon 
cassia 
powder in 
The objective of the 
present study was to 
investigate the anti-
diabetic effect of 
cinnamon cassia 
powder in type 2 
diabetic patients 
Sixty type 2 diabetic 
patients were 
randomized either 
1.5 g/d of cinnamon 
cassia powder or 
placebo. Both 
groups were in 
combination with 
their current 
 Cinnamon 
cassia 1.5 g 
daily (frequency 
not specified) 
 Placebo 1.5 g 
daily(frequency 
and substance 
of placebo not 
specified) 
 HbA1c 
 FPG 
 Lipids 
 LFT 
 
After a 12-week period, 
HbA1c was decreased 
similarly in both groups from 
8.14% to 7.76% in the 
cinnamon group and from 
8.06% to 7.87% in the 
placebo group. This was not 
found statistically 
significantly different. 
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type 2  
diabetes 
mellitus. 
Journal of 
the Medical 
Association 
of Thailand= 
Chotmaihet  
thangphaet, 
89, S200-5. 
 
treatment 
(metformin or 
sulfonylurea) 
according to single 
blind randomized, 
placebo-control trial 
in a 12-week period. 
Efficacy was 
evaluated by HbA1c 
fasting plasma 
glucose, Lipid 
profile, BUN, 
creatinine, liver 
function test and 
adverse effects were 
recorded. 
 However the proportion of 
patients achieving HbA1c < 
or = 7% was also greater in 
patients receiving cinnamon 
compared with patients 
receiving placebo, 
nevertheless, it was not found 
statistically significantly 
different (35% vs 15%, x2 = 
3.14, p > 0.05). No significant 
intergroup differences were 
observed in lipid profile, 
fasting plasma glucose except 
in SGOT 27.1 (8.75) to 22.1 
(5) in cinnamon group and 
24.08 (8.5) to 23.63 (8.88) in 
the placebo group (p = 0.001). 
14. Khan, R., 
Khan, Z., & 
Shah, S. 
(2010). 
Cinnamon 
may reduce 
glucose, lipid 
and 
cholesterol  
level in type 
2 diabetic 
individuals. 
This study was 
initiated to confirm 
the researcher’s 
previous findings that 
cinnamon intake 
reduces glucose, 
triglycerides and 
cholesterol in type 2 
diabetic individuals. 
 
This study consisted 
of 14 type 2 
diabetics randomly 
divided into two 
equal groups.  One 
group was assigned 
1.5 g cinnamon daily 
and the was assigned 
1.5 g of placebo 
daily 
 Ground 
cinnamon one 
0.5 g capsule at 
breakfast, 
lunch, and 
dinner for total 
of 1.5 g daily 
 Placebo of maze 
flour one 0.5 g 
capsule at 
breakfast, 
lunch, and 
 FBG 
 Lipids 
 
Results show significant 
reduction in FBG (P, 0.05), 
triglycerides (P < 0.05) and 
cholesterol levels (P < 0.05), 
but no significant reduction in 
HDL and LDL levels. 
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430-433. 
 
dinner for total 
of 1.5 g daily 
15. Roussel, 
A. M., 
Hininger, I., 
Benaraba, R., 
Ziegenfuss, 
T. N., & 
Anderson, R. 
A. (2009).  
Antioxidant 
effects of a 
cinnamon 
extract in 
people with 
impaired 
fasting 
glucose that 
are  
overweight 
or obese. 
Journal of 
the American 
College of 
Nutrition, 
28(1), 16-21. 
To determine the 
effects of a dried 
aqueous extract of 
cinnamon on 
antioxidant status of 
people with impaired 
fasting glucose that 
are overweight or 
obese. 
Twenty-two 
subjects, with 
impaired fasting 
blood glucose with 
BMI ranging from 
25 to 45, were 
enrolled in a double-
blind placebo-
controlled trial. 
Subjects were 
divided randomly 
into two groups and 
given capsules 
containing either a 
placebo or 250 mg 
of an aqueous 
extract of cinnamon 
(Cinnulin PF) two 
times per day for 12 
weeks. 
 Cinnamon 
cinnulin PF 250 
mg BID for 12 
weeks 
 Placebo 250 mg 
BID for 12 
weeks 
(substance in 
placebo not 
specified) 
 Blood sample 
times – 0, 6, and 
12 weeks  
 FBG 
 Fasting insulin 
 Plasma 
malondialdehyde 
(MDA) 
concentrations 
 Plasma 
antioxidant 
status ( evaluated 
by FRAP assay) 
 
FRAP and plasma thiol (SH) 
groups increased, while 
plasma MDA levels decreased 
in subjects receiving the 
cinnamon extract. Effects 
were larger after 12 than 6 
weeks. There was also a 
positive correlation (r = 0.74; 
p = 0.014) between MDA and 
plasma glucose. 
Significant reduction was 
seen in the fasting glucose of 
the cinnamon group compared 
to the placebo group (P < 
0.05).  No significant 
reduction was seen in the 
fasting insulin in either group. 
 
